Delving into the Latest Updates on Fluindione with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(4-fluorophenyl)indene-1,3-dione, Previscan

Target

VKOR

Action

inhibitors

Mechanism

VKOR inhibitors(Vitamin K epOxide reductase complex subunit 1 inhibitors)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication

Blood Coagulation Disorders

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H9FO2

InChIKeyNASXCEITKQITLD-UHFFFAOYSA-N

CAS Registry957-56-2

The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA) in older adults (≥ 80 years) suffering from non valvular atrial fibrillation and living in community or nursing home settings.
An observational multicenter prospective inception cohort will be conducted within the PRESAGE-Network, an ongoing active network on drug safety in older adults in France involving a sample of general practitioners (GPs) and pharmacists, for an active surveillance of drug safety in older adults. GPs and pharmacists will prospectively include all octo+ patients they care for, newly treated with an oral anticoagulant (VKA or DOA) for nv AF and will follow them during 2 years at least.

Start Date01 Feb 2015

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT00966290

/ CompletedPhase 4IIT

Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study

Background: Whether the management of vitamin K antagonists (VKA) therapy by general practitioners with the collaboration of anticoagulation clinics (ACC) provides better clinical outcomes than that accomplished by general practitioners alone (usual care [UC] management) is not clear.
Objectives: To compare ACC-based shared-care management with UC management of VKA therapy with respect to clinical events.
Patients/Methods: Open, randomized, multicenter study in patients starting VKA therapy for at least three months. The primary study outcome is a composite of confirmed symptomatic thromboembolic or major bleeding events. All-cause mortality is a secondary outcome. All outcomes are reviewed by a central, independent adjudication committee.

Start Date01 Feb 2003

Sponsor / Collaborator

Toulouse University Hospital

100 Clinical Results associated with Fluindione

Login to view more data

100 Translational Medicine associated with Fluindione

Login to view more data

100 Patents (Medical) associated with Fluindione

Login to view more data

276

Literatures (Medical) associated with Fluindione

01 May 2025·Journal of Pharmaceutical and Biomedical Analysis

Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases

Article

Author: Delavenne, Xavier ; Bidat, Carolyne ; Escal, Jean ; Hodin, Sophie ; Duband, Sébastien ; Drague, Angélique ; Dellinger, Sandrine ; Feliu, Catherine

Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.

24 Jan 2025·European Journal of Organic Chemistry

Synthesis of 1,4‐Naphthoquinones via Palladium(II)‐Catalyzed Tertiary C−H Alkylation of Olefins Followed by C−C Bond Cleavage

Author: Li, Wenguang ; Chang, Mengfan ; Zhang, Xu ; Xu, Xuefeng ; Li, Ting ; Ni, Tongtong

AbstractAn efficient method has been developed for the preparation of 1,4‐naphthoquinones via a palladium‐catalyzed reaction of 2‐aryl‐1,3‐indandiones with olefins. This reaction involves the tertiary C−H alkylation of 2‐aryl‐1,3‐indandiones with olefins to produce a tertiary alcohol, followed by C−C bond cleavage.

01 Dec 2024·Biomedicine & Pharmacotherapy

Population pharmacokinetics of unfractionated heparin and multivariable analysis of activated clotting time in patients undergoing radiofrequency ablation of atrial fibrillation

Article

Author: Lesaffre, François ; Feliu, Catherine ; Dubuisson, Florine ; Djerada, Zoubir ; Konecki, Celine ; Guillou, Sophie ; Faroux, Laurent ; Labdaoui, Moad

INTRODUCTIONAtrial fibrillation (AF) increases cardiovascular morbidity and mortality. To reduce thrombosis and bleeding risks, and due to high variability of unfractionated heparin (UFH) effect, activated clotting time (ACT) is used during radiofrequency catheter ablation (RFCA) of AF to guide UFH dose. This study aimed to develop a population PK-PD model and perform multivariable analysis in order to identify the most significant covariates associated with interindividual variability of UFH.METHODSElectronic medical records from 668 patients undergoing RFCA were analyzed, including relevant covariates. The relationship between UFH dose and ACT and the impact of the main covariates were characterized using a mixed-effect PK-PD model. Multivariable analysis was then used to identify predictors of ACT 15 minutes after UFH administration (ACT15).RESULTSA two-compartment PK model with linear elimination and a direct Emax PD model with a baseline and sigmoidicity best described the observed ACT values. Pretreatment with dabigatran, warfarin, or fluindione significantly influenced baseline ACT. Pretreatment with vitamin K antagonists or low molecular weight heparin explained Emax variability. The multivariable model identified baseline ACT, initial UFH dose, and previous anticoagulant as the main predictors of ACT15. Model evaluation through resampling and external validation showed accurate ACT15 predictions.CONCLUSIONThis study presents the first population PK-PD model characterizing the relationship between UFH doses and ACT during RFCA, along with multivariable analysis. Additionally, predictive calculators for ACT15 and UFH dose based on patient and procedural characteristics were developed, enhancing personalized anticoagulation management during RFCA.

100 Deals associated with Fluindione

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fluindione	B01AA12	DB13136

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Blood Coagulation Disorders	France	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2014	Not Applicable	Nephrosis	7	Fluindione	vmbozglljw(nsfjrkkvlk) = WRN was initially suspected in patients treated with warfarin while initial diagnosis was incorrect in 4 of 5 patients treated with fluindione (acute interstitial nephritis for 3 patients and acute tubular necrosis for the last patient) etdetatvyq (juzgpqufjl ) View more	Negative	11 Nov 2014